11/14/2024
3:53 PM | Fulcrum Therapeutics (Subject)
Nantahala Capital Management, LLC (Filed by)
| Form SCHEDULE 13G | |
11/14/2024
3:25 PM | Fulcrum Therapeutics (Subject)
SUVRETTA CAPITAL MANAGEMENT, LLC (Filed by)
| Form SC 13G/A | |
11/14/2024
5:15 AM | Fulcrum Therapeutics (Subject)
RTW INVESTMENTS, LP (Filed by)
| Form SC 13G/A | |
11/13/2024
6:05 AM | Fulcrum Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/13/2024
6:10 AM | Fulcrum Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
11/12/2024
2:51 PM | Fulcrum Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
11/04/2024
10:49 AM | Fulcrum Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
|
10/07/2024
10:37 AM | FMR LLC (Filed by)
Fulcrum Therapeutics (Subject)
| Form SC 13G/A | |
09/24/2024
3:05 PM | Fulcrum Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/23/2024
3:15 PM | Fulcrum Therapeutics (Issuer)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
Shah Rajeev M. (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
09/20/2024
3:21 PM | Fulcrum Therapeutics (Subject)
TCG Crossover GP II, LLC (Filed by)
| Form SC 13G | |
09/16/2024
7:21 PM | Fulcrum Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13G/A | |
09/12/2024
11:43 AM | Fulcrum Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/23/2024
3:16 PM | Fulcrum Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13G/A | |
08/22/2024
3:02 PM | Fulcrum Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/31/2024
6:55 AM | Fulcrum Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
07/31/2024
6:10 AM | Fulcrum Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/31/2024
6:15 AM | Fulcrum Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
07/08/2024
7:00 AM | Fulcrum Therapeutics (Issuer)
Sapir Alex (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/17/2024
3:37 PM | Fulcrum Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/13/2024
6:15 AM | Fulcrum Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/13/2024
6:05 AM | Fulcrum Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/09/2024
3:10 PM | Fulcrum Therapeutics (Issuer)
Tourangeau Greg (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/25/2024
11:15 PM | Fulcrum Therapeutics (Filer)
| Form EFFECT | |
03/20/2024
3:10 PM | Fulcrum Therapeutics (Issuer)
Horn Patrick Taylor (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
03/20/2024
3:15 PM | Fulcrum Therapeutics (Issuer)
Horn Patrick Taylor (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/08/2024
5:00 PM | Fulcrum Therapeutics (Subject)
Tourangeau Greg (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/08/2024
5:05 PM | Fulcrum Therapeutics (Issuer)
Tourangeau Greg (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/27/2024
6:01 AM | Fulcrum Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/14/2024
6:53 AM | Fulcrum Therapeutics (Subject)
RTW INVESTMENTS, LP (Filed by)
| Form SC 13G/A | |
02/13/2024
11:08 AM | Fulcrum Therapeutics (Subject)
SUVRETTA CAPITAL MANAGEMENT, LLC (Filed by)
| Form SC 13G/A | |
02/07/2024
6:44 AM | ADAGE CAPITAL PARTNERS GP, L.L.C. (Filed by)
Fulcrum Therapeutics (Subject)
| Form SC 13G/A | |
01/30/2024
8:00 PM | Fulcrum Therapeutics (Issuer)
Oltmans Curtis Gale (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/30/2024
8:05 PM | Fulcrum Therapeutics (Issuer)
Musso Alan A (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/30/2024
8:10 PM | Fulcrum Therapeutics (Issuer)
Tourangeau Greg (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
